Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Return on Equity (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Return on Equity data on record, last reported at 0.4% in Q3 2025.

  • For Q3 2025, Return on Equity fell 27.0% year-over-year to 0.4%; the TTM value through Sep 2025 reached 0.4%, down 27.0%, while the annual FY2023 figure was 0.67%, 155.0% up from the prior year.
  • Return on Equity reached 0.4% in Q3 2025 per CYCN's latest filing, up from 0.43% in the prior quarter.
  • Across five years, Return on Equity topped out at 2.19% in Q3 2023 and bottomed at 2.16% in Q3 2022.
  • Average Return on Equity over 5 years is 0.42%, with a median of 0.43% recorded in 2025.
  • Peak YoY movement for Return on Equity: soared 435bps in 2023, then plummeted -232bps in 2024.
  • A 5-year view of Return on Equity shows it stood at 1.06% in 2021, then tumbled by -30bps to 1.37% in 2022, then skyrocketed by 144bps to 0.61% in 2023, then tumbled by -112bps to 0.07% in 2024, then tumbled by -446bps to 0.4% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.4% in Q3 2025, 0.43% in Q2 2025, and 0.24% in Q1 2025.